By Bilal Hafeez 13-08-2020
In: hive-exclusives | COVID-19 Equities

Equities Care About Vaccines, Not Second Waves

(2 min read)
Resize text:


Numerous countries are experiencing second waves of COVID-19 infections – not that you would know from their equity market performance. Take the US. Its second wave (or acceleration of the first) started towards the end of May and ended in early July. Over that period, stocks were still up around 6%. Admittedly, there was a short-lived correction of 7%, but that was considerably smaller than the 34% decline seen around the first surge in cases (Chart 1).

Outside of the US, a number of countries are experiencing second waves from Poland to Hong Kong to Australia. Yet their equity performances have not been too different to countries without second waves. On average, second wave countries have seen their stocks rise 4.5% over the past two months. This compares to 5% for countries either still in their first wave or having flattened the curve. Therefore, you would be hard-pressed to discern whether a country is experiencing a second wave from relative equity performance.

TO READ THIS HIVE EXCLUSIVE
SUBSCRIBE TO MACRO HIVE PRIME

£39/month thereafter

MONTHLY MEMBERSHIP

FREE TRIAL

£39/month thereafter

YEARLY MEMBERSHIP

SAVE 20%

£374.40/year

BOTH MEMBERSHIPS INCLUDE

  • Hive Exclusives
  • Hive Indicators
  • Prime Community
  • Deep Dives
  • Hive Podcasts
  • Prime Q&A
Have a Promotional Code? Click here to enter your code

DETAILS

Members

PAYMENT

  • Pay with your credit card via Stripe.


    Add New Card

ORDER BREAKDOWN

Product Total
Monthly  × 1 £39.00 / month with 1 month free trial
Subtotal £0.00
Total £0.00
Recurring totals
Subtotal £39.00 / month
Recurring total £39.00 / month
First renewal: 22nd November 2020
Free one month trial period. After, you�ll be charged at the monthly rate unless you cancel your membership otherwise.

For access to our Slack Chat Room, where we discuss all things markets with our researchers and subscribers

START YOUR FREE TRIAL